Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
Pfizer Inc.and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) approved […]
Nationwide Roll-Out of NHS High Street Heart Checks to Save Thousands of Lives
Thousands of lives will be saved thanks to more blood pressure checks in high street […]
Government Launches First UK-wide Antibody Surveillance Programme
Thousands of adults a day will be given free access to antibody tests through a […]
Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo Clinical-Stage Assets
Elixiron Immunotherapeutics, Inc., a privately held company developing therapeutics for cancer, neurological diseases and inflammatory […]
First Monoclonal Antibody Treatment for COVID-19 Approved for Use in the UK
Following on from a thorough review of the evidence carried out by the MHRA, and […]
CUNY SPH and NYC Health Department Awarded $3.3 Million to Study New HIV Intervention
The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public […]
Roche Receives FDA Approval for First Companion Diagnostic to Identify dMMR Solid Tumour Patients Eligible for Anti-PD-1 Immunotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval […]
Therapeutic Solutions International Identifies and Files Patent on Novel Mechanism of Action of Its FDA Phase III Cleared JadiCell™ Treatment of COVID-19 and Delta Variant
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today novel data and filing of a […]
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline and Expand Single Cell Analysis Drug Development Platform
Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the completion of a $58 […]
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more